Pfizer Inc. (PFE) Receives Average Recommendation of “Hold” from Analysts
Shares of Pfizer Inc. (NYSE:PFE) have been assigned an average rating of “Hold” from the twenty-three research firms that are presently covering the stock, MarketBeat.com reports. Two research analysts have rated the stock with a sell rating, twelve have assigned a hold rating and nine have issued a buy rating on the company. The average 12-month price target among analysts that have issued a report on the stock in the last year is $41.94.
PFE has been the topic of a number of analyst reports. Societe Generale reiterated a “neutral” rating and set a $39.00 price objective on shares of Pfizer in a research note on Wednesday, May 30th. Cantor Fitzgerald initiated coverage on Pfizer in a research note on Thursday, June 7th. They set an “overweight” rating and a $45.00 price objective on the stock. Credit Suisse Group set a $39.00 price objective on Pfizer and gave the company a “neutral” rating in a research note on Monday, June 11th. Morgan Stanley reiterated a “buy” rating and set a $43.00 price objective on shares of Pfizer in a research note on Monday, June 11th. Finally, Zacks Investment Research upgraded Pfizer from a “hold” rating to a “buy” rating and set a $41.00 price objective on the stock in a research note on Tuesday, July 3rd.
In related news, insider Laurie J. Olson sold 10,214 shares of the business’s stock in a transaction dated Monday, August 13th. The stock was sold at an average price of $41.00, for a total transaction of $418,774.00. Following the completion of the transaction, the insider now directly owns 72,672 shares in the company, valued at $2,979,552. The transaction was disclosed in a document filed with the SEC, which is available through this link. Also, insider Sally Susman sold 40,381 shares of the business’s stock in a transaction dated Friday, July 20th. The stock was sold at an average price of $37.22, for a total value of $1,502,980.82. Following the transaction, the insider now owns 155,377 shares of the company’s stock, valued at $5,783,131.94. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 761,230 shares of company stock valued at $29,054,690. 0.06% of the stock is owned by company insiders.
Shares of PFE opened at $42.96 on Monday. The firm has a market capitalization of $252.46 billion, a price-to-earnings ratio of 16.21, a PEG ratio of 2.04 and a beta of 0.96. The company has a debt-to-equity ratio of 0.41, a quick ratio of 0.91 and a current ratio of 1.16. Pfizer has a 1 year low of $33.20 and a 1 year high of $43.00.
Pfizer (NYSE:PFE) last released its quarterly earnings data on Tuesday, July 31st. The biopharmaceutical company reported $0.81 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.74 by $0.07. Pfizer had a return on equity of 25.35% and a net margin of 42.35%. The company had revenue of $13.47 billion for the quarter, compared to analyst estimates of $13.30 billion. During the same period in the previous year, the company posted $0.67 EPS. The firm’s revenue for the quarter was up 4.4% compared to the same quarter last year. research analysts anticipate that Pfizer will post 2.99 earnings per share for the current fiscal year.
The firm also recently announced a quarterly dividend, which was paid on Tuesday, September 4th. Investors of record on Friday, August 3rd were given a dividend of $0.34 per share. This represents a $1.36 annualized dividend and a yield of 3.17%. The ex-dividend date was Thursday, August 2nd. Pfizer’s payout ratio is 51.32%.
Pfizer Inc discovers, develops, manufactures, and sells healthcare products worldwide. It operates in two segments, Pfizer Innovative Health (IH) and Pfizer Essential Health (EH). The IH segment focuses on the development and commercialization of medicines and vaccines, and consumer healthcare products in various therapeutic areas, including internal medicine, vaccines, oncology, inflammation and immunology, and rare diseases, as well as consumer healthcare, such as over-the-counter brands comprising dietary supplements, pain management, gastrointestinal, and respiratory and personal care.
Featured Story: Asset Allocation Models, Which is Right For You?
Receive News & Ratings for Pfizer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer and related companies with MarketBeat.com's FREE daily email newsletter.